Hemera Biosciences is a leading brand specializing in tackling Age-Related Macular Degeneration (AMD), which is the primary cause of blindness in individuals aged 50 and above. AMD is a progressive disease that affects the macula, the central part of the retina, impairing crucial functions such as reading, driving, recognizing faces and colors, and perceiving fine details. With approximately 1 in 4 people aged 70 or above, and 1 in 3 people aged 80 or above affected by AMD, the magnitude of the problem is overwhelming.

By 2020, it's estimated that AMD will impact around 196 million individuals worldwide. Hemera Biosciences aims to address both forms of AMD: Dry AMD and Wet AMD. Dry AMD is characterized by yellow deposits known as drusen, while Wet AMD involves the growth of abnormal blood vessels in the macula.

Hemera Biosciences offers FDA-approved treatments for Wet AMD, successfully blocking the growth of these blood vessels and preventing permanent vision loss. Unfortunately, there is currently no FDA-approved treatment available for Dry AMD. Hemera Biosciences is committed to combating the prevalence of AMD and continuously improving the lives of those affected.

Contact Hemera Biosciences at Info@hemerabiosciences. com or visit their location in Waltham, MA for more information